10-Q: Palatin Technologies Faces Delisting Amidst Ongoing Financial Challenges, Reports Q3 2025 Results

Palatin Technologies reports Q3 2025 results, highlighting ongoing losses, a delisting notice from NYSE American, and efforts to secure additional funding.

Summary

• Palatin Technologies reported a net loss of $4.8 million for the three months ended March 31, 2025, and $15.1 million for the nine months ended the same date.
• The company's cash and cash equivalents stood at $2.5 million as of March 31, 2025, while current liabilities totaled $10.0 million.
• Palatin received a delisting notice from NYSE American due to the low selling price of its common stock, and trading was suspended on May 7, 2025.
• Since May 8, 2025, the company's common stock has been trading on the Pink Market of the OTC Markets Group under the symbol PTNT.
• The company is evaluating strategies to obtain additional funding, including equity financing, debt issuance, and expense reductions.
• There is substantial doubt about the company's ability to continue as a going concern for one year from the date the financial statements were issued.
• Research and development expenses decreased to $3.8 million for the three months and $12.9 million for the nine months ended March 31, 2025, compared to the previous year.
• Selling, general, and administrative expenses also decreased due to the sale of Vyleesi.
• The company completed a public offering on May 8, 2025, raising net proceeds of $931,715.
• The company is developing several product candidates, including a co-administration of bremelanotide with tirzepatide for obesity, PL9643 for dry eye disease, and PL8177 for ulcerative colitis.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to ongoing losses, delisting from NYSE American, and concerns about the company's ability to continue as a going concern. While there are some positive clinical trial results, the overall financial situation is precarious.

Positives

• Co-administration of bremelanotide with tirzepatide demonstrated increased weight loss over tirzepatide alone in Phase 2 trials.
• PL8177 showed promising results in Phase 2 clinical trials for ulcerative colitis, with one-third of patients achieving clinical remission.
• The company is actively engaged in discussions with potential partners and licensees for its ocular condition products.
• Selling, general, and administrative expenses decreased due to the sale of Vyleesi.

Negatives

• Palatin Technologies has incurred operating losses and negative cash flows since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company received a delisting notice from NYSE American due to the low selling price of its common stock.
• The company's cash and cash equivalents are low compared to its current liabilities.
• The company does not have a recurring source of revenue following the sale of Vyleesi.

Risks

• The company's ability to obtain additional financing on acceptable terms is uncertain.
• The company may never achieve or maintain profitability.
• Increases in costs and delays in conducting human clinical trials could adversely affect the company's business.
• The company's business is subject to risks related to geopolitical instability, economic uncertainty, and supply chain disruptions.
• The company faces risks related to competing products and technologies.
• The company is involved in a legal proceeding with H.C. Wainwright & Co., LLC.

Future Outlook

Palatin Technologies expects that its existing cash and cash equivalents will be sufficient to fund its operations into the second half of calendar year 2025, but additional funding will be needed to complete clinical trials and regulatory applications.

Management Comments

• Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company's MC1r and MC4r programs, and development of other portfolio products.
• Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for one year from the date these consolidated financial statements are issued.
• The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses.

Industry Context

Palatin Technologies operates in the competitive biopharmaceutical industry, facing challenges common to early-stage companies, including the need for significant funding, successful clinical trial outcomes, and regulatory approvals. The delisting from NYSE American and the shift to the OTC Pink Market reflect the financial pressures and market skepticism surrounding the company's prospects.

Comparison to Industry Standards

• Palatin's situation can be compared to other small-cap biopharmaceutical companies facing financial difficulties, such as those listed on the OTC markets after failing to meet listing requirements on major exchanges.
• Companies like Aeterna Zentaris Inc. and Evofem Biosciences, Inc. have faced similar challenges related to delisting and raising capital.
• The success of Palatin's clinical programs, particularly the co-administration of bremelanotide with tirzepatide, will be crucial for attracting investment and partnerships, similar to how positive clinical data can drive valuations for companies like Viking Therapeutics, Inc. in the obesity and metabolic disease space.
• The company's ability to secure partnerships for its ocular condition products will be critical, as seen with companies like Kala Pharmaceuticals, Inc. that have sought collaborations to advance their ophthalmic programs.

Legal Proceedings

• H.C. Wainwright & Co., LLC filed a complaint against Palatin Technologies, Inc. for breach of contract, seeking monetary damages and the award of warrants.

Stakeholder Impact

• Shareholders face the risk of further stock dilution through additional financing activities.
• Employees face uncertainty due to the company's financial instability and potential cost reductions.
• Customers and partners face uncertainty regarding the company's ability to continue developing and commercializing its products.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to evaluate strategies to obtain additional funding.
• The company will continue clinical development of its MC1r and MC4r programs.
• The company is currently assessing the viability of an appeal against the NYSE Regulations decision to delist the Company’s common stock.

Key Dates

Keywords

Palatin Technologies, financial results, delisting, going concern, clinical trials, Vyleesi, bremelanotide, PL9643, PL8177, financing, melanocortin receptor, biopharmaceutical